Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with nebulized glycopyrrolate in the USA: a real-world data analysis

被引:3
|
作者
Niu, Xiaoli [1 ]
Divino, Victoria [2 ]
Sharma, Sanjay [1 ]
Dekoven, Mitch [2 ]
Anupindi, Vamshi Ruthwik [2 ]
Dembek, Carole [1 ]
机构
[1] Sunovion Pharmaceut Inc, 84 Waterford Dr, Marlborough, MA 01752 USA
[2] IQVIA, Falls Church, VA USA
关键词
Real-world data; real-world effectiveness; nebulized glycopyrrolate; long-acting muscarinic antagonist; chronic obstructive pulmonary disease; health resource utilization; ASSESS CLINICAL CHARACTERISTICS; INHALATION TECHNIQUE; COPD EXACERBATIONS; INHALER DEVICES; TRIPLE THERAPY; UNITED-STATES; MANAGEMENT; INITIATION; PATTERNS; ICD-9-CM;
D O I
10.1080/13696998.2020.1845185
中图分类号
F [经济];
学科分类号
02 ;
摘要
Aims This study compared medication use, healthcare resource utilization (HRU), and exacerbations among individuals with chronic obstructive pulmonary disease (COPD) who initiated glycopyrrolate/eFlow Closed System nebulizer 25 mcg/mL glycopyrrolate (hereafter GLY) in a real-world setting before and after treatment initiation. Materials and methods Retrospective claims and hospital charge master data were used to identify individuals >= 40 years of age diagnosed with COPD who initiated GLY between 1 April 2018 and 28 February 2019 (first prescription claim = index date). Patients were excluded if they had >= 1 asthma diagnosis in the 6-month pre-index period. The proportion of patients with COPD-related medications, other outpatient HRU, hospitalizations, and exacerbations were compared between the 6-month pre-index and 6-month follow-up periods. Among patients utilizing the service, per-person utilization rates were compared between the two periods. Results Among patients initiating GLY (n = 767), the mean age was 71.4 years, 56.1% were female, and the mean Charlson Comorbidity Index score was 2.0. The mean number of GLY claims per person was 3.8 during the follow-up period. Compared to the pre-index period, a lower proportion of patients had claims for COPD medications including oral corticosteroids (62.1% vs. 69.1%, p = .0001) and fixed-dose SAMA/SABA (26.1% vs. 33.0%, p < .0001) and a higher proportion of patients had claims for LABA (29.7% vs. 22.6%, p < .0001) during the follow-up period. Fewer patients had >= 1 COPD-related physician office visit (42.4% vs. 49.8%, p < .0001), radiology test (40.7% vs. 46.5%, p = .005), or moderate exacerbation (48.0% vs. 53.2%, p = .01) after initiating GLY. Among patients with linkage to inpatient data (n = 316), fewer were hospitalized (7.9% vs. 13.0%, p = .037) and hospital length of stay was shorter (1.9 vs. 3.6 days, p = .017) after initiating GLY/eFlow. Conclusions Among patients initiating GLY in a real-world setting, COPD medications, hospitalizations, other HRU, and exacerbations decreased after treatment initiation compared with the 6-month pre-index period.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [1] Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis
    Tracey Weiss
    Aimee M. Near
    Xiaohui Zhao
    Dena Rosen Ramey
    Tania Banerji
    Handing Xie
    Steven D. Nathan
    [J]. BMC Pulmonary Medicine, 23
  • [2] Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis
    Weiss, Tracey
    Near, Aimee M.
    Zhao, Xiaohui
    Ramey, Dena Rosen
    Banerji, Tania
    Xie, Handing
    Nathan, Steven D.
    [J]. BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [3] Exacerbations in Patients with Chronic Obstructive Pulmonary Disease Treated with Nebulized Glycopyrrolate versus Other Long-Acting Muscarinic Antagonists: A US Healthcare Administrative Database Analysis
    Wang, J.
    Niu, X.
    Sharma, S.
    Chandra, R.
    Nagle, G.
    McMahon, W.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [4] Risk Of Exacerbations In Chronic Obstructive Pulmonary Disease Patients Treated With Nebulized Laba Versus Nebulized Saba Treatments
    Yeaw, J.
    Bollu, V.
    Karafilidis, J.
    Cen, J.
    Hines, D.
    Makin, C.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [5] Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
    Laliberte, Francois
    Raut, Monika
    Yang, Xiaoqin
    Germain, Guillaume
    Nahar, Akash
    Desai, Kaushal D.
    MacKnight, Sean D.
    Sen, Shuvayu S.
    Duh, Mei Sheng
    [J]. TARGETED ONCOLOGY, 2021, 16 (01) : 85 - 94
  • [6] Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
    François Laliberté
    Monika Raut
    Xiaoqin Yang
    Guillaume Germain
    Akash Nahar
    Kaushal D. Desai
    Sean D. MacKnight
    Shuvayu S. Sen
    Mei Sheng Duh
    [J]. Targeted Oncology, 2021, 16 : 85 - 94
  • [7] Burden of pulmonary hypertension due to chronic obstructive pulmonary disease: Analysis of exacerbations and healthcare resource utilization in the United States
    Klinger, James R.
    Wu, Benjamin
    Morland, Kellie
    Classi, Peter
    Fiano, Ryan
    Grabich, Shannon
    [J]. RESPIRATORY MEDICINE, 2023, 219
  • [8] IMPACT OF ROFLUMILAST ON HEALTH CARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN REAL-WORLD SETTINGS
    Corman, S.
    Wan, Y.
    Sun, S. X.
    Gao, X.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A175 - A175
  • [9] Azithromycin to prevent exacerbations of chronic obstructive pulmonary disease: a study in the real-world setting
    Olivo Neto, Pedro
    Spolidoro, Bruno Baron
    Marcolin, Gabriela
    Berton, Danilo Cortozi
    Knorst, Marli Maria
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [10] Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event
    Navaie, Maryam
    Celli, Bartolome R.
    Xu, Zhun
    Cho-Reyes, Soojin
    Dembek, Carole
    Gilmer, Todd P.
    [J]. CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2019, 6 (04): : 297 - 307